双调蛋白、ST2与REG3α生物标志物风险算法对急性GVHD患者非复发死亡率的预测
在同种异体造血细胞移植后急性GVHD患者中,于GVHD诊断时检测血清ST2、REG3α和AREG浓度,训练队列341例构建含1至3个标志物组合的12个月NRM预测算法,验证队列374例比较性能;仅含ST2+REG3α的算法曲线下面积最高(0.757)、正确分类患者最多(75%),对Minnesota标准风险GVHD及移植后环磷酰胺预防患者风险分层更准确;仅含AREG的算法对Minnesota高风险GVHD分层更准确;三标志物合并未改善性能。
要点
- 在训练队列341例中构建含1至3个标志物组合的12个月NRM预测算法,验证队列374例比较性能。
- 仅含ST2+REG3α的算法曲线下面积最高(0.757),正确分类患者最多(75%)。
- 仅含AREG的算法对Minnesota高风险GVHD患者风险分层更准确。
核心结论
- 仅含ST2+REG3α的算法对12个月NRM discriminating 最强,曲线下面积0.757,正确分类75%患者,对Minnesota标准风险GVHD及移植后环磷酰胺预防患者分层更准确;仅含AREG的算法对Minnesota高风险GVHD分层更准确;三标志物合并未改善性能。
研究设计与样本
- 在715例于GVHD诊断时采集血清的患者中,按移植日期分为训练队列(2004-2015年,n=341)和验证队列(2015-2017年,n=374),用酶联免疫吸附试验检测ST2、REG3α和AREG浓度。
- 训练队列用于构建含1至3个标志物所有可能组合的12个月NRM预测算法,并以对应于一致性概率的阈值进行风险分层。
- 仅用验证队列(n=374)基于受试者工作特征曲线下面积、正确分类患者比例、敏感性和特异性等指标比较算法性能。
主要发现
- 所有算法均为12个月NRM的强判别器,无论患者是否接受全身治疗(n=321)。
- 仅含ST2+REG3α的算法曲线下面积最高(0.757),正确分类患者最多(75%),对Minnesota标准风险GVHD及移植后环磷酰胺预防患者风险分层更准确。
- 仅含AREG的算法对Minnesota高风险GVHD患者风险分层更准确。
- 将ST2、REG3α和AREG合并为单一算法未改善性能。
关键数值与推荐
- 原文未报告具体阈值数值及一致性概率对应值。
- 原文未报告各算法敏感性、特异性具体数值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance.
引用
- Etra A, El Jurdi N, Katsivelos N, et al. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD. Blood Adv. 2024. PMID: 38640195. doi:10.1182/bloodadvances.2023011049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。